# Epsilogen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epsilogen

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.epsilogen.com
- Total disclosed funding: $61M
- Latest round: Series B (Aug 29, 2024)
- Investors on record: 8

## About

Based in London, UK, and founded in 2016 by Sophia Karagiannis, Epsilogen Ltd, f.k.a. IGEM Therapeutics Limited, a.k.a. Epsilogen is a developer of immunoglobulin E antibodies that are used for the treatment of solid tumors including greater potency, enhanced tumor access, and a long tissue half-life. In March 2022, Epsilogen Ltd raised GBP 30.8 million in a Series B funding led by Novartis Venture Fund, with participation from 3B Future Health Fund, British Patient Capital, Caribou Property Limited, Schroders Capital, ALSA Ventures, and Epidarex Capital. As of January 2023, Tim Wilson is the CEO of the company.

The company’s product line includes MOv18 IgE, which is in phase I clinical trial in folate receptor alpha-positive cancer patients; EPS 201 for the treatment of breast and gastric cancers; and IGEG-X. Epsilogen is developing IGEG platform technology based on combining the power of IgE (immunoglobulin E) and IgG (immunoglobulin G) antibody molecules.

The company plans to use its proceeds from March 2022 to continue the clinical development of MOv18 IgE in platinum-resistant ovarian cancer and support further development of IgE-based antibody candidates to treat cancers.

## Funding rounds

- Series B, Aug 29, 2024, $16M — Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund, British Patient Capital, ALSA Ventures
- Series B, Feb 27, 2022, $41M — Schroders Capital, Albion Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund, British Patient Capital, ALSA Ventures, Caribou Property Limited
- Series A, Mar 31, 2020, $3.7M — Epidarex Capital

## Investors

- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A, Series B
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B
- Albion Capital — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series B
- British Patient Capital — Series B
- ALSA Ventures (https://capitalatlas.ai/funds/alsa-ventures) — Series B
- Caribou Property Limited — Series B